ETFs & Funds
View as an RSS Feed
What's Going On With Questcor?
QCOR has been through this before. Unfortunately, Citron Reasearch has consistently put out misleading information (I believe this is the third time in the last six months). Each time, the stock has rebounded. Citron Research specializes in short-selling and searches for companies that have a high short float. QCORs short float is around 35% and Citron realizes the volatility of this stock and any sort of bad news will batter it. I would really like to see the positions that Citron takes prior to reporting this material. Investors need to be aware of these situations and do their own research. If you are an invested in QCOR, you should realize that nothing has really changed. The conference call reaffirmed that, and you will see this stock rise to the $40 range within a few weeks. It will certainly encounter some resistance at this point, but earnings will certainly curtail investor fears.
Sep 20, 2012. 06:57 PM
Link to Comment
) weakness a
, says Leerink Swann. The firm says it's confirmed with Aetna (
) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written.
View news story
This is straight from the Questcor (
) Press Release:
"Currently, the Company does not believe that the bulletin represents a material change in insurance coverage for Acthar by Aetna. During 2012, Aetna has accounted for approximately 5% of the Company's shipped prescriptions for Acthar. Based on its current assessment of the Clinical Policy Bulletin, the Company does not believe that the bulletin will have a material impact on the Company's results of operations."
Sep 19, 2012. 04:45 PM
Link to Comment